Axsome Therapeutics, Inc. (AXSM)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Revenue | 150,042 | 121,463 | 104,762 | |
| Selling, general and administrative | 130,280 | 120,787 | 95,564 | |
| Research and development | 49,541 | 44,785 | 45,388 | |
| Cost of revenue (excluding amortization and depreciation) | 13,448 | 9,789 | 8,437 | |
| Intangible asset amortization | 1,589 | 1,572 | 1,606 | |
| Loss (gain) in fair value of contingent consideration | -8,102 | 1,512 | 16,391 | |
| Total operating expenses | 186,756 | 178,445 | 167,386 | |
| Loss from operations | -36,714 | -56,982 | -62,624 | |
| Interest expense, net | -1,834 | -2,431 | -1,978 | |
| Loss on debt extinguishment | -10,385 | - | - | |
| Loss before income taxes | -48,933 | -59,413 | -64,602 | |
| Income tax benefit | -1,000 | - | - | |
| Income tax benefit | -960 | - | - | |
| Net loss | -47,973 | -59,413 | -64,602 | |
| Net loss per common share, basic | -0.97 | -1.22 | -1.34 | |
| Net loss per common share, diluted | -0.97 | -1.22 | -1.34 | |
| Weighted average common shares outstanding, basic | 49,442,001 | 48,871,163 | 48,140,519 | |
| Weighted average common shares outstanding, diluted | 49,442,001 | 48,871,163 | 48,140,519 | |